Delving into the Latest Updates on Hainan Yuekang Biomedicine Co Ltd with Synapse

Overview

Tags

Neoplasms

Respiratory Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

EGFR L858R x EGFR T790M x EGFR exon 20 x EGFR-Ex19del	1

评价YK-029A片的最大耐受剂量（MTD）、剂量限制性毒性（DLT），确定II期临床试验推荐的给药方案和剂量。研究YK-029A片药代动力学特征，分析药代动力学及其与药效（PK/PD）/毒性（PK/AE）之间的关系，检测代谢产物。评价YK-029A片治疗对经既往表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKI）治疗后T790M突变获得性耐药和疾病进展的晚期非小细胞肺癌患者的初步疗效。

[Translation]

To evaluate the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of YK-029A tablets, and determine the recommended dosing regimen and dose for Phase II clinical trials. To study the pharmacokinetic characteristics of YK-029A tablets, analyze the relationship between pharmacokinetics and pharmacodynamics (PK/PD)/toxicity (PK/AE), and detect metabolites. To evaluate the preliminary efficacy of YK-029A tablets in patients with advanced non-small cell lung cancer with acquired resistance and disease progression to T790M mutation after previous epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment.

Start Date12 Sep 2018

Sponsor / Collaborator

Hainan Yuekang Biomedicine Co Ltd

100 Clinical Results associated with Hainan Yuekang Biomedicine Co Ltd

Login to view more data

0 Patents (Medical) associated with Hainan Yuekang Biomedicine Co Ltd

Login to view more data

100 Deals associated with Hainan Yuekang Biomedicine Co Ltd

Login to view more data

100 Translational Medicine associated with Hainan Yuekang Biomedicine Co Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 May 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3

1

Login to view more data